Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Guidance for the Transition of clinical trials from the Clinical Trials Directive to the Clinical Trials Regulation Version 2
EU-Guidance-for-the-Transition-of-Clinical-Trials-from-the-Clinical-Trials-Directive-to-the-Clinical-Trials-Regulation-Version-2-21-Dec-2023_22Dec2023-1Download
Ryan McArthur 29 December 2023 All news
  • ← Artificial intelligence workplan to guide use of AI in medicines regulation
  • Hemovigilance: ANSM changes the way blood donors report adverse events →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • User’s booklet – ANSM
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2024
  • Questions and Answers on the Windsor Framework and medicines for human use (updated 25 October 2024)
Copyright © 2018 - Pharmya - Legal terms - Quality Policy